Ultrasound Guided Serratus Anterior Versus Erector Spinae Block in Pain Alleviation in Acute Herpes Zoster
1 other identifier
interventional
120
0 countries
N/A
Brief Summary
Acute herpes zoster pain is very severe . Conventional analgesics may be of no value. Regional blocks may play a role
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jul 2024
Shorter than P25 for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 15, 2024
CompletedFirst Posted
Study publicly available on registry
June 26, 2024
CompletedStudy Start
First participant enrolled
July 5, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 15, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
April 15, 2025
CompletedJune 27, 2024
June 1, 2024
9 months
June 15, 2024
June 26, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
pain score
Visual analogue scale from 0 to 10. 0= NO pain, 1-3=mild tolerable pain, 4-6= moderate pain, 7-10= severe untearable pain.
immediate after injection, 1 week, 1, 3 months
Secondary Outcomes (3)
Number of patients with pain recurrence
1 week, 1, and 3 months
analgesic consumption
1 week, 1, and 3 months
Incidence of treatment related adverse events
immediately after injection
Study Arms (3)
Control group
NO INTERVENTION800 mg acyclovir, 5 times / day, orally administered, for one week, acetaminophen 1000 mg per day, topical calamine lotion)
Erector spinae group
ACTIVE COMPARATOR800 mg acyclovir, 5 times / day, orally administered, for one week, acetaminophen 1000 mg per day, topical calamine lotion)+ 25 ml bupivacaine 0.25% plus 8 mg dexamethasone
Serratus anterior group
ACTIVE COMPARATOR800 mg acyclovir, 5 times / day, orally administered, for one week, acetaminophen 1000 mg per day, topical calamine lotion)+ 25 ml bupivacaine 0.25% plus 8 mg dexamethasone
Interventions
Ultrasound guided thoracic erector spinae block
Eligibility Criteria
You may qualify if:
- Adult population between 30 and 75 years old.
- Unilateral painful thoracic herpetic eruption of less than one week duration.
- VAS more than or equal 4, persistent pain in spite of proper antiviral and analgesic therapy, (800 mg oral acyclovir, 5 times per day, for one week), pregabalin 300 mg per day, acetaminophen 1000 mg per day, topical calamine lotion).
You may not qualify if:
- Diabetic patients.
- Painful herpetic eruptive vesicles more than one week.
- Abdominal herpetic eruptions.
- Non-compliant on anti-viral (bulbar palsy for example).
- Co-malignancy or radiotherapy.
- Steroid therapy \> 5 mg prednisolone or its equivalent.
- Infections or hematoma at site of injection.
- Coagulopathy (chronic kidney or liver disease, clopidogrel use).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Minia Universitylead
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Ass professor anesthesia and pain
Study Record Dates
First Submitted
June 15, 2024
First Posted
June 26, 2024
Study Start
July 5, 2024
Primary Completion
April 15, 2025
Study Completion
April 15, 2025
Last Updated
June 27, 2024
Record last verified: 2024-06